Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
10.21% $6.69
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 25.00 mill |
EPS: | 12.31 |
P/E: | 0.540 |
Earnings Date: | May 12, 2024 |
SharesOutstanding: | 3.74 mill |
Avg Daily Volume: | 0.0376 mill |
RATING 2024-03-28 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Sell | |
P/E: | Sell | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | |
Gr.Profit | n/a | n/a | n/a | |||
Ebit | ||||||
Asset | ||||||
Debt | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 0.540 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
0.09x |
Company: PE 0.540 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$5.97 (-10.72%) $-0.717 |
Date: 2024-03-29 |
Expected Trading Range (DAY) |
---|
$ 6.00 - 7.38 ( +/- 10.27%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-28 | Hamill John P. | Buy | 3 365 | Common Stock |
2024-03-28 | Hamill John P. | Buy | 13 460 | Stock Options (Right to Buy) |
2024-03-28 | Gilad Oren | Buy | 6 725 | Common Stock |
2024-03-28 | Gilad Oren | Buy | 26 900 | Stock Options (Right to Buy) |
2024-03-13 | Hamill John P. | Buy | 1 010 | Common Stock |
INSIDER POWER |
---|
89.49 |
Last 96 transactions |
Buy: 13 026 874 | Sell: 1 205 176 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $6.69 (10.21% ) |
Volume | 0.0284 mill |
Avg. Vol. | 0.0376 mill |
% of Avg. Vol | 75.50 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.